Corrigendum: MRI radiomics predicts progression-free survival in prostate cancer

Affiliations

¹ Affiliated Hospital, Inner Mongolia Medical University, Hohhot, China.
² Department of Pharmaceuticals Diagnosis, GE Healthcare (China), Shanghai, China.
³ Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Published Erratum

Yushan Jia et al. Front Oncol. 2023.

. 2023 Jan 13:12:1125641.

doi: 10.3389/fonc.2022.1125641. eCollection 2022.

¹ Affiliated Hospital, Inner Mongolia Medical University, Hohhot, China.
² Department of Pharmaceuticals Diagnosis, GE Healthcare (China), Shanghai, China.
³ Department of Radiology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.974257.].

Keywords: magnetic resonance imaging; predictions; progression-free survival; prostate cancer; radiomics.

MRI radiomics predicts progression-free survival in prostate cancer.
Jia Y, Quan S, Ren J, Wu H, Liu A, Gao Y, Hao F, Yang Z, Zhang T, Hu H. Jia Y, et al. Front Oncol. 2022 Aug 30;12:974257. doi: 10.3389/fonc.2022.974257. eCollection 2022. Front Oncol. 2022. PMID: 36110963 Free PMC article.